Topline results of the Phase 1b/2a study were presented during a poster session at the 2023 Neuroscience Education Institute (NEI) Congress Delpor’s drug/device combination risperidone implant (DLP-114) was well tolerated for up to 12 months Average PANSS and CGI-I scores were similar…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.